Navigation Links
VIVUS Reports First Quarter 2011 Financial Results
Date:5/2/2011

ons contained in the label and the extent of the Risk Evaluation and Mitigation Strategies program; uncertainties of litigation and intellectual property and patent protection; reliance on sole-source suppliers; limited sales and marketing resources and dependence upon third parties; risks related to the development of innovative products; risks related to the failure to obtain FDA or foreign authority clearances or approval; noncompliance with FDA or foreign regulations; and our dependence on the performance of our collaborative partners. As with any pharmaceutical in development, there are significant risks in the development, the regulatory approval, and commercialization of new products. There are no guarantees that our response to the FDA's CRL or the results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy and subsequent meetings and communications will be sufficient to satisfy the FDA's safety concerns, that the FDA will not require us to conduct any additional  prospective studies or retrospective observational studies, or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ending December 31, 2010, and periodic reports filed with the Securities and Exchange Commission.VIVUS, Inc.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share amounts)(unaudited)Three Months EndedMarch 31March 3120112010Operating expenses:Research and development$
4,480$
,211General and administrative5,4285,164Total operating expenses9,90815,375Loss from operations(9,908)(15,375)Interest and other income (expense), net

42(1,233)Loss from continuing operations before income taxes(9,866)(16,608)Provision for income taxes(1)(1)Net loss from cont
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. VIVUS to Present at Four Upcoming Investor Conferences in May
2. VIVUS to Present at the 10th Annual Needham Healthcare Conference
3. Data on VIVUS QNEXA to be Presented in Six Posters at The Obesity Societys Annual Meeting
4. VIVUS to Present at Four Upcoming Investor Conferences
5. VIVUS to Present at Two Upcoming Investor Conferences
6. VIVUS Reports Third Quarter 2009 Highlights and Financial Results
7. VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
8. VIVUS to Present at Four Upcoming Healthcare Conferences
9. VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
10. VIVUS to Present at the Needham and Company Life Sciences Conference
11. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... worldwide rely on sophisticated equipment, trained personnel, and ... areas against terrorist attacks. A revolutionary new electronic ... make their job much easier. , The groundbreaking ... Tel Aviv University ,s School of Chemistry and ... the Herzliya company Tracense, picks up the scent ...
(Date:7/24/2014)... processes prefer to settle into equilibriuma state of ... the realm of non-equilibrium conditions where new possibilities ... and phases, such as temperature fluctuations, freezing and ... regulate their body temperature, airplanes to fly, and ... , But even though these conditions exist naturally ...
(Date:7/24/2014)... , July 24, 2014 SRI International ... with the National Institute of Allergy and Infectious Diseases ... conduct preclinical development of potential therapies for HIV infection ... to treat HIV and AIDS and the complications and ... microbicides for preventing sexual transmission of HIV. ...
(Date:7/24/2014)... LANSING, Mich. , July 24, 2014  Neogen ... today that future forecasts of its potential revenue from ... conference call to investors and analysts on July 22, ... questioned by analysts regarding this research. "It ... answer questions about the potential of a new type ...
Breaking Biology Technology:Nano-sized chip 'sniffs out' explosives far better than trained dogs 2New approach to form non-equilibrium structures 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3Neogen comments on SenesTech 2
... SectorWatch.biz announces the,availability of MarketStats on public equities ... Investors can view all of SectorWatch.biz MarketStats ... Click on MarketStats, Today,s MarketStats on Healthcare ... Bulletin Board: CVBT), Boston,Scientific Corp. (NYSE: BSX ...
... DIEGO, Feb. 14 Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ... and,year-end 2007 financial results on Wednesday, February 20, 2008, ... a conference call and webcast to discuss its fourth,quarter ... its,development programs on Wednesday, February 20, 2008 at 5:00 ...
... Feb. 14 AspenBio Pharma,Inc. (Nasdaq: APPY ) ... drugs and diagnostics for animals and humans, has been,invited ... Growth Stock,Conference. The conference will be held February 18-21, ... California., Roth Capital Partners Stock Conferences are one ...
Cached Biology Technology:SectorWatch.biz Issues MarketStats on CVBT, BSX, MDT, CXM and DNA 2Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results 2AspenBio Pharma to Present at the Roth Capital Partners 20th Annual Growth Stock Conference 2
(Date:7/27/2014)... at Barts Cancer Institute have found that targeting a ... more effective, according to research published in Nature ... part of Queen Mary University of London, have found ... the body to repair itself after chemotherapy or radiotherapy, ... researchers removed FAK from blood vessels that grew in ...
(Date:7/25/2014)... 100,000s of people lived on the land now called ... control the availability of plants they used for food, ... fire to maintain desired habitat and natural resources. , ... Pacific Southwest Station, will lead a field trip ... the Ecological Society of America,s 99th Annual Meeting, in ...
(Date:7/25/2014)... study published online in the International Journal of ... to preventing cervical cancer based on findings showing successful ... of a discrete population of cells in the cervix. ... looked at squamocolumnar junction cells, or SCJ cells. These ... implicated as the origins of cervical cancer. A research ...
Breaking Biology News(10 mins):New drug target can break down cancer's barrier against treatment 2Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3Clearing cells to prevent cervical cancer 2
... The New York Genome Center (NYGC) announced today ... become an Associate Member, joining NYGC,s growing consortium of ... new ways to utilize genomic data for better detection, ... NYSCF working with the genomic scientists at NYGC will ...
... an excellent economics teacher, but some would be surprised to ... is cleaner than the first breath they ever took. ... that improvements in U.S. air quality since 1990 have sparked ... to air pollution. Pope was a member of a large ...
... of popular soft drinks, alters the brain,s perception of ... determine the difference between sugar and artificial sweeteners, according ... official journal of the American Gastroenterological Association. ... and artificial sweeteners can leave the sweet taste of ...
Cached Biology News:New York Genome Center announces the New York Stem Cell Foundation as an Associate Member 2New York Genome Center announces the New York Stem Cell Foundation as an Associate Member 3Death & disability from air pollution down 35 percent in the US 2Carbonation alters the mind's perception of sweetness 2
... FX provides complete solutions for ... With 96-, 384-, and independent ... either single or dual arm ... maximum speed and flexibility for ...
... fixed-angle microcentrifuge rotor at RCF up ... filters consist of a membrane-containing filter ... filter by centrifugation for bacteria removal, ... of cells from media and DNA ...
... System provides high-throughput, quantitative gene expression analysis ... patented priming strategy overcomes the biases that ... a few genes at a time. ... and more samples per run, removing bottlenecks ...
... Detergent-OUT Kit is a simple high performance ... Removes detergents without significant dilution of ... solution on the Detergent-OUT Spin column and ... Med column is suitable for removing detergents ...
Biology Products: